drugset / Trial / NCT05108779
QLF32004 Injection for the Treatment of Patients With Advanced Malignant Tumors
NaSequentialOpen-labelTreatment
Summary
To determine the safety, tolerability, and recommended dose (RP2D) of QLF32004 in patients with advanced malignancies.
Timeline
- Start
- 2021-11-09
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QLF32004 | Unknown | — | — |
Indications
No indication recorded.